Pamidronate administration improves the secondary hyperparathyroidism due to “Bone hunger syndrome” in a patient with osteoblastic metastases from prostate cancer

The so‐called Bone Hunger Syndrome is a metabolic derangement that sometimes complicates the natural history of prostate cancer patients with osteoblastic bone metastases. An excessive bone formation leads to calcium entrapment in bone and the subsequent increase of parathyroid hormone (PTH) levels, in response to calcium demand. PTH elevation stimulates the osteoclasts in sites distant from those involving the tumor, leading to osteomalacia.